A Phase 1, Open-Label, Dose Escalation Study of MGA271 in Combination With Ipilimumab in Patients With Melanoma, Non-Small Cell Lung Cancer, and Other Cancers

Trial Profile

A Phase 1, Open-Label, Dose Escalation Study of MGA271 in Combination With Ipilimumab in Patients With Melanoma, Non-Small Cell Lung Cancer, and Other Cancers

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 12 Aug 2018

At a glance

  • Drugs Enoblituzumab (Primary) ; Ipilimumab
  • Indications Breast cancer; Colon cancer; Head and neck cancer; Lung cancer; Malignant melanoma; Mesothelioma; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Prostate cancer; Renal cell carcinoma; Soft tissue sarcoma; Squamous cell cancer; Thyroid cancer; Urogenital cancer
  • Focus Adverse reactions
  • Sponsors MacroGenics
  • Most Recent Events

    • 07 May 2018 According to a MacroGenics media release, the company expects to present clinical data from this study in the second half of 2018.
    • 02 Mar 2018 Planned End Date changed from 1 Mar 2018 to 1 Sep 2018.
    • 02 Mar 2018 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top